A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of BTRC4017A Administered Intravenously in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers
Phase of Trial: Phase I
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs BTRC-4017A (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Genentech
- 04 Apr 2019 Planned End Date changed from 31 May 2024 to 30 Jun 2023.
- 04 Apr 2019 Planned primary completion date changed from 31 May 2024 to 30 Jun 2023.
- 07 Mar 2018 New trial record